Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.6593
+0.0146 (2.26%)
At close: Jan 21, 2026, 4:00 PM EST
0.6800
+0.0207 (3.14%)
After-hours: Jan 21, 2026, 7:59 PM EST
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
91
Market Cap
79.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMUX News
- 14 days ago - Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PRNewsWire
- 2 months ago - Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - PRNewsWire
- 2 months ago - Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Immunic to Participate in Industry and Investor Conferences in November - PRNewsWire
- 4 months ago - Immunic to Participate in Scientific and Investor Conferences in October - PRNewsWire
- 4 months ago - Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis - PRNewsWire
- 4 months ago - Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis - PRNewsWire
- 4 months ago - Immunic to Participate in Investor and Scientific Conferences in September - PRNewsWire